Task Zero G and ICP: Invasive and Noninvasive ICP Monitoring of Astronauts on the ISS (Williams)
Last Published:  04/20/22 11:43:24 AM (Central)
Short Title: Direct ICP
Responsible HRP Element: Human Health Countermeasures
Collaborating Org(s):
Space Medicine Medical Operations (SMMO)
Funding Status: Active - Currently funded and in progress
Procurement Mechanism(s):
Solicited
Aims:

Original Aims
Specific Aim 1: Determine whether ICP in space is elevated in comparison to baseline ICP on Earth, and whether ICP after return to Earth differs from baseline values by measuring ICP in astronauts before, during, and after an ISS mission by invasive methods.

Specific Aim 2: Validate noninvasive ICP measurement methods and their correlation with invasive ICP before, during, and after spaceflight, and to quantify their error of measurement.

Specific Aim 3: Determine the correlation of ICP changes to other indicators of SANS by collecting biomarkers of  SANS for correlation to ICP.

This study was merged with Zanello's "Multimodal Modeling towards Noninvasive Assessment of Intracranial Pressure in Weightlessness and Biomarker Identification of Predisposition to VIIP Syndrome."   https://humanresearchroadmap.nasa.gov/Tasks/task.aspx?i=2058 .  This work will now be completed by Dr. Williams. The aims from the formerly Zanello study are below.

Additional Aims
Specific Aim 1 
(Hypothesis #1 and #2)

- To develop and validate a noninvasive ICP estimation (nICP) approach for a specific

population of crewmembers based on a noninvasive ICP framework (NICF). The anticipated

input parameters may include: arterial blood pressure (ABP), electrocardiogram signals, cerebral

blood flow velocity (CBFV), heart and ventilation rate, tympanic membrane displacement by

Cochlear and Cerebrospinal Fluid Pressure (CCFP), ophthalmic artery blood pressure by

Vittamed. The NICF has been only tested using ABP and CBFV data from brain injury patients.

The additional noninvasive data elements provide different aspects of cerebral physiology under

influence of ICP. Therefore, integrating them under the NICF is very likely to improve nICP

accuracy.

Specific Aim 2 (Hypothesis #2)

- To longitudinally estimate ICP in crew members before, during and after spaceflight using the

model developed in Aim 1.

Specific Aim 3 (Hypothesis #3)

- To use novel methods of mRNA and microRNA profiling to identify candidate urinary and

plasma biomarkers that align with SANS-related physiologic variables.

Specific Aim 4 (Hypothesis #4)

-To measure and correlate novel biomarkers in urine and blood of crew members with measures

of estimated ICP, pre-, in- and post-flight.

-To use all noninvasive measures plus biomarkers as input to build a predictive model that will

inform the likelihood of a given crew member developing SANS post flight.








Mappings